The advantages to developing these small molecule CCR5 inhibitors as topical agents to prevent HIV infection include 1) the rigorous safety testing that they have undergone during trials of systemic administration, 2) the fact that they are relatively inexpensive to produce and 3) their lack of agonist activity on the chemokine receptor. Here, CCR5 is linked to HIV infectious disease.